Introduction to the Acquisition
The drug manufacturer Regeneron Pharmaceuticals has acquired the gene testing company 23Andme for $256 million through a bankruptcy auction. This move has raised concerns regarding the protection of customer data, as 23Andme has collected genetic information from over 15 million customers who purchased its DNA test kits online.
Data Protection and Compliance
Regeneron has stated that it will comply with data protection guidelines and applicable laws regarding the use of customer data. The company is prepared to provide detailed information on the intended use of the data to a judicial overseer. This assurance comes after legislators expressed concerns that millions of customers’ genetic data could be sold to unscrupulous buyers during the bankruptcy proceedings.
Background on 23Andme
23Andme had agreed to allow a court-appointed supervisor to oversee the handling of customer genetic information and its security policies during the bankruptcy process. The company had faced challenges due to weak demand for its ancestry services and a data breach in 2023, which exposed millions of genetic data records.
Terms of the Acquisition
As part of the agreement, Regeneron will acquire all units of 23Andme, except for Lemonaid Health, which will be spun off from the genetic testing company. After completing the transaction, 23Andme will continue to operate as a 100% direct or indirect subsidiary of Regeneron.
Expected Outcome and Timeline
The companies expect to complete the deal in the third quarter. This acquisition will likely have significant implications for the genetic testing industry and the protection of customer data. Regeneron’s commitment to complying with data protection guidelines will be closely monitored to ensure that the genetic information of 23Andme’s customers is handled responsibly.
